Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MSH6 negative||pancreatic cancer||sensitive||Pembrolizumab||Guideline||Actionable||Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org).||detail... 37678671|
|MSH6 negative||pancreatic cancer||sensitive||Pembrolizumab||Phase II||Actionable||In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 18.2% (4/22, 1 complete response and 3 partial responses), a duration of response that was not reached, a median progression-free survival of 2.1 mo, and a median overall survival of 3.7 mo in pancreatic cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067).||35680043|
|PubMed Id||Reference Title||Details|
|ESMO Clinical Practice Guidelines||Full reference...|
|(35680043)||Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.||Full reference...|
|(37678671)||Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.||Full reference...|